Article
Multidisciplinary Sciences
Zhiyang Li, Heng Zhang, Yujie Sun, Zhuangzhuang Feng, Bijia Cui, Jingxia Han, Yinan Li, Huijuan Liu, Tao Sun
Summary: Angiogenesis plays a crucial role in embryologic development, growth, and tissue repair, but dysregulation of this process is a hallmark of various pathologies, including cancer. Existing methods for evaluating cell vascular formation are often limited to static analysis, leading to bias. Researchers have developed code scripts to study the dynamic angiogenesis process, allowing for the screening of drugs that can affect various parameters of vascular formation. Animal experiments have confirmed the efficacy of these drugs in inhibiting blood vessel formation, providing a new perspective for angiogenesis research and drug development.
Article
Oncology
Xin Li, Xinyu Su, Chen Yan, Yuanyuan Ma, Heng Li, Jianhong Xia, Hongliang Li, Qian Jiang, Liqing Zhou, Zhengyun Zou
Summary: This study discusses the role of VEGF in radiotherapy resistance of ESCC. It found that serum VEGF levels were related to clinical response, and knocking down VEGF expression improved the sensitivity of ESCC cells to radiation.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Multidisciplinary Sciences
Nunzia Caporarello, Jisu Lee, Tho X. Pham, Dakota L. Jones, Jiazhen Guan, Patrick A. Link, Jeffrey A. Meridew, Grace Marden, Takashi Yamashita, Collin A. Osborne, Aditya Bhagwate, Steven K. Huang, Roberto F. Nicosia, Daniel J. Tschumperlin, Maria Trojanowska, Giovanni Ligresti
Summary: Vascular dysfunction plays a significant role in aging and chronic diseases, but its involvement in lung repair and fibrosis remains unclear. In this study, the authors identified the endothelial transcription factor ERG as a mediator of vascular repair, whose function declines in aged lungs, resulting in sustained fibrosis. These findings highlight the importance of understanding the mechanisms underlying vascular dysfunction in lung fibrosis and provide potential targets for therapeutic interventions.
NATURE COMMUNICATIONS
(2022)
Article
Dentistry, Oral Surgery & Medicine
Y. Zhang, S. Lin, J. Liu, Q. Chen, J. Kang, J. Zhong, M. Hu, M. S. Basabrain, Y. Liang, C. Yuan, C. Zhang
Summary: This study found that dental pulp stem cells can increase the lifespan and perfusion of blood vessels. The results revealed that dental pulp stem cells inhibit endothelial cell sprouting by activating the TEK tyrosine kinase (Tie2) signaling and regulating the expression levels of vascular endothelial (VE)-cadherin and vascular endothelial growth factor receptor 2 (VEGFR2).
JOURNAL OF DENTAL RESEARCH
(2023)
Article
Biochemistry & Molecular Biology
Barbara Vizio, Ornella Bosco, Ezio David, Gian Paolo Caviglia, Maria Lorena Abate, Martina Schiavello, Angela Pucci, Antonina Smedile, Gianluca Paraluppi, Renato Romagnoli, Enrico Lupia, Graziella Bellone, Giuseppe Montrucchio
Summary: The study revealed that THPO and VEGF-A expression levels were significantly elevated in tumor tissues compared to liver cirrhosis tissues in HCC patients. There was a linear correlation between THPO and VEGF-A transcripts in HCC, indicating a potential interdependent regulation between the two growth factors in promoting cellular growth.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Chemistry, Multidisciplinary
Prashant Jain, Chethan D. Shanthamurthy, Shani Leviatan Ben-Arye, Sharon Yehuda, Sharvani S. Nandikol, Hirekodathakallu Thulasiram, Vered Padler-Karavani, Raghavendra Kikkeri
Summary: A potential heparan sulfate (HS) ligand was discovered to target several growth factors using specific HS tetrasaccharide ligands. One tetrasaccharide ligand showed strong binding with the VEGF(165) growth factor, and in vitro experiments demonstrated the therapeutic potential of these synthetic HS ligands by inhibiting vascular endothelial cell proliferation, migration, and angiogenesis in the presence of VEGF(165) and the specific tetrasaccharides.
CHEMICAL COMMUNICATIONS
(2021)
Article
Chemistry, Multidisciplinary
Yang Liu, Linyu Long, Fanjun Zhang, Xuefeng Hu, Jieyu Zhang, Cheng Hu, Yunbing Wang, Jianguo Xu
Summary: The study introduced a GelMA microneedle platform for sustained and controlled local delivery of AAV-VEGF, which achieved homogeneous distribution and high transfection efficiency in ischemic brains. Results showed that MNs loaded with AAV-VEGF increased VEGF expression in the brain cortex and enhanced functional angiogenesis and neurogenesis.
JOURNAL OF CONTROLLED RELEASE
(2021)
Article
Oncology
Sang Hyun Seo, Kyung Joo Cho, Hye Jung Park, Hyemi Kim, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim
Summary: The study demonstrates that DKK1 promotes angiogenesis and tumorigenesis in HCC by upregulating the VEGFR2-mediated mTOR/p70S6K signaling pathway.
AMERICAN JOURNAL OF CANCER RESEARCH
(2021)
Article
Medicine, Research & Experimental
Zhi Xia, Jian Xiao, Ziyu Dai, Qiong Chen
Summary: This study found that highly expressed mPR alpha in LUAD tissues enhances the activation of the cAMP/JAK/STAT3 signaling pathway and increases HIF1 alpha-induced VEGF secretion in the tumor microenvironment, promoting HUVEC migration and tube formation under hypoxia.
JOURNAL OF TRANSLATIONAL MEDICINE
(2022)
Article
Clinical Neurology
Carlos Escudero, Jesenia Acurio, Eduardo Lopez, Andres Rodriguez, Antonia Benavente, Evelyn Lara, Steven J. Korzeniewski
Summary: Circulating VEGF levels were found to be elevated 24-48 hours after acute ischemic stroke and were associated with prognosis of moderate to severe disability at 6 months. Combining VEGF with interleukin 6 and C-reactive protein significantly improved predictive performance compared to using VEGF alone.
EUROPEAN JOURNAL OF NEUROLOGY
(2021)
Review
Ophthalmology
Akiyoshi Uemura, Marcus Fruttiger, Patricia A. D'Amore, Sandro De Falco, Antonia M. Joussen, Florian Sennlaub, Lynne R. Brunck, Kristian T. Johnson, George N. Lambrou, Kay D. Rittenhouse, Thomas Langmann
Summary: VEGFR1 and its ligands play important roles in angiogenesis and microinflammatory cascades within the retina, but the mechanisms of their actions remain unclear, the competition for receptor binding and heterodimerization complicates the understanding of their relative contributions.
PROGRESS IN RETINAL AND EYE RESEARCH
(2021)
Review
Biochemistry & Molecular Biology
Mannon Geindreau, Francois Ghiringhelli, Melanie Bruchard
Summary: VEGF plays a crucial role in tumor growth by promoting angiogenesis and modulating the immune response. Clinical approval has been given to therapies targeting VEGF for the treatment of various cancers.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Mechanics
Jyotsana Priyadarshani, Prasoon Awasthi, Pratyaksh Karan, Soumen Das, Suman Chakraborty
Summary: This study presents a simulation mimicking tumor angiogenesis microenvironment on-chip, aiming to establish favorable conditions for gradients of vascular endothelial growth factor. The model platform explores different responses of endothelial cells in a micro-confined fluidic environment, showing potential significance for organ-on-a-chip assays, disease modeling, and optimizing anti-angiogenic therapies.
Article
Oncology
Bahadir Koylu, Fatih Tekin, Burak Yasin Aktas, Saadettin Kilickap, Deniz Koksal
Summary: This study reported a case of chylothorax in an advanced RCC patient receiving pazopanib therapy. The development of chylothorax was attributed to pazopanib treatment. Chylothorax significantly regressed after discontinuation of the medication.
Review
Oncology
Indu Passi, Koushal Billowria, Bhupinder Kumar, Pooja A. Chawla
Summary: The article introduces the background of renal cell carcinoma and different types of treatment, focusing on the mechanism of action and side effects of the anti-renal cell carcinoma drug Tivozanib. Tivozanib is a highly selective and potent oral tyrosine kinase inhibitor of vascular endothelial growth factor receptors (VEGFRs), suitable for the treatment of renal cell carcinoma and can be used in combination with other drugs with minimal side effects. Further research needs to be conducted in multicenter clinical trials.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY
(2023)
Article
Biochemistry & Molecular Biology
Pier Vitale Nuzzo, Jacob E. Berchuck, Keegan Korthauer, Sandor Spisak, Amin H. Nassar, Sarah Abou Alaiwi, Ankur Chakravarthy, Shu Yi Shen, Ziad Bakouny, Francesco Boccardo, John Steinharter, Gabrielle Bouchard, Catherine R. Curran, Wenting Pan, Sylvan C. Baca, Ji-Heui Seo, Gwo-Shu Mary Lee, M. Dror Michaelson, Steven L. Chang, Sushrut S. Waikar, Guru Sonpavde, Rafael A. Irizarry, Mark Pomerantz, Daniel D. De Carvalho, Toni K. Choueiri, Matthew L. Freedman
Article
Oncology
Kerry L. Reynolds, Samuel J. Klempner, Aparna Parikh, Ephraim P. Hochberg, M. Dror Michaelson, Meghan J. Mooradian, Richard J. Lee, Tara E. Soumerai, Gabriela Hobbs, Zofia Piotrowska, David B. Sykes, Anna F. Farago, Aditya Bardia, Rachel P. Rosovsky, David P. Ryan
Article
Oncology
Chung-Han Lee, Robert J. Motzer, Hilary Glen, M. D. Michaelson, James Larkin, Yukinori Minoshima, Michio Kanekiyo, Hiroki Ikezawa, Pallavi Sachdev, Corina E. Dutcus, Yasuhiro Funahashi, Martin H. Voss
Summary: No biomarkers have been established to predict treatment efficacy in renal cell carcinoma (RCC). In an exploratory analysis, composite biomarker scores (CBSs) were constructed and found to significantly predict progression-free survival (PFS) and overall survival (OS) in patients with metastatic RCC receiving lenvatinib-plus-everolimus treatment. The 5-factor CBS may identify patients who would benefit from this treatment approach, but further validation is needed.
BRITISH JOURNAL OF CANCER
(2021)
Article
Urology & Nephrology
Thomas E. Hutson, M. Dror Michaelson, Timothy M. Kuzel, Neeraj Agarwal, Ana M. Molina, James J. Hsieh, Ulka N. Vaishampayan, Ran Xie, Urmi Bapat, Weifei Ye, Rohit K. Jain, Mayer N. Fishman
Summary: The combination of lenvatinib plus everolimus as a first-line treatment showed promising anticancer activity for patients with advanced non-clear cell renal cell carcinoma, with a relatively high objective response rate and manageable treatment-related adverse events.
Article
Biochemistry & Molecular Biology
Toni K. Choueiri, Todd M. Bauer, Kyriakos P. Papadopoulos, Elizabeth R. Plimack, Jaime R. Merchan, David F. McDermott, M. Dror Michaelson, Leonard J. Appleman, Sanjay Thamake, Rodolfo F. Perini, Naseem J. Zojwalla, Eric Jonasch
Summary: The HIF-2 alpha inhibitor belzutifan shows promising clinical activity and a favorable safety profile in heavily pre-treated patients with renal cell carcinoma, suggesting it may offer an effective treatment option. The drug was well tolerated with a confirmed objective response rate of 25% and a median progression-free survival of 14.5 months in patients with ccRCC.
Article
Oncology
Daniel E. Lage, M. Dror Michaelson, Richard J. Lee, Joseph A. Greer, Jennifer S. Temel, Christopher J. Sweeney
Summary: The research showed that older men with metastatic hormone-sensitive prostate cancer (mHSPC) had similar overall survival benefits and clinical outcomes when receiving docetaxel + androgen deprivation therapy (ADT) compared to younger men. Docetaxel chemotherapy may be considered as a favorable treatment option for older men with mHSPC who are fit for chemotherapy.
PROSTATE CANCER AND PROSTATIC DISEASES
(2021)
Correction
Biochemistry & Molecular Biology
Toni K. Choueiri, Todd M. Bauer, Kyriakos P. Papadopoulos, Elizabeth R. Plimack, Jaime R. Merchan, David F. McDermott, M. Dror Michaelson, Leonard J. Appleman, Sanjay Thamake, Rodolfo F. Perini, Naseem J. Zojwalla, Eric Jonasch
Article
Oncology
Sumanta K. Pal, Paul H. Frankel, Amir Mortazavi, Matthew Milowsky, Ulka Vaishampayan, Mamta Parikh, Yung Lyou, Peng Weng, Rahul Parikh, Benjamin Teply, Robert Dreicer, Hamid Emamekhoo, Dror Michaelson, Christopher Hoimes, Tian Zhang, Sandy Srinivas, William Y. Kim, Yujie Cui, Edward Newman, Primo N. Lara
Summary: This study aimed to determine whether the selective ATR inhibitor, berzosertib, could enhance the activity of cisplatin with gemcitabine. The results showed that, despite higher hematologic toxicities in the experimental arm, there was no significant prolongation of progression-free survival in patients with metastatic urothelial cancer compared to the control arm.
Review
Oncology
Robert M. Stern, M. Dror Michaelson, Erica L. Mayer, Aric D. Parnes, Annemarie E. Fogerty, Ann S. LaCasce, Ryan D. Nipp
Summary: The COVID-19 pandemic has impacted graduate medical education training programs, requiring reorganization of structures to minimize risks and ensure well-being. A survey of first-year fellows at Dana-Farber Cancer Institute/Mass General Brigham was conducted to assess the program's response to COVID-19, providing valuable feedback and lessons learned. This effort represents a new approach in evaluating a hematology-oncology program's response to the pandemic.
JCO ONCOLOGY PRACTICE
(2021)
Article
Oncology
Harish Seethapathy, Sarah Street, Ian Strohbehn, Meghan Lee, Sophia H. Zhao, Nifasha Rusibamayila, Donald F. Chute, Xin Gao, Marc D. Michaelson, Osama E. Rahma, Toni K. Choueiri, Brad McGregor, Guru Sonpavde, Cristina Salabao, Marina D. Kaymakcalan, Xiao Wei, Shruti Gupta, Shveta Motwani, David E. Leaf, Kerry L. Reynolds, Meghan E. Sise
Summary: This study investigated the impact of immune checkpoint inhibitors on kidney function in patients with renal cell carcinoma and urothelial carcinoma. The results showed that acute kidney injury and sustained eGFR loss were common, and immune-related adverse events may be a novel risk factor for kidney function decline in patients receiving ICIs.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Oncology
Robert J. Motzer, Eric Jonasch, Neeraj Agarwal, Ajjai Alva, Michael Baine, Kathryn Beckermann, Maria Carlo, Toni K. Choueiri, Brian A. Costello, Ithaar H. Derweesh, Arpita Desai, Yasser Ged, Saby George, John L. Gore, Naomi Haas, Steven L. Hancock, Payal Kapur, Christos Kyriakopoulos, Elaine T. Lam, Primo N. Lara, Clayton Lau, Bryan Lewis, David C. Madoff, Brandon Manley, M. Dror Michaelson, Amir Mortazavi, Lakshminarayanan Nandagopal, Elizabeth R. Plimack, Lee Ponsky, Sundhar Ramalingam, Brian Shuch, Zachary L. Smith, Jeffrey Sosman, Mary A. Dwyer, Lisa A. Gurski, Angela Motter
Summary: The NCCN Guidelines for Kidney Cancer provide comprehensive treatment recommendations for renal cell carcinoma, covering screening, diagnosis, staging, surgery, and systemic therapy. Tumor histology and risk stratification of patients are important factors in treatment selection, considering efficacy, safety, evidence, and accessibility of agents.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
(2022)
Article
Oncology
Edwin Choy, Gregory M. Cote, M. Dror Michaelson, Lori Wirth, Justin F. Gainor, Alona Muzikansky, Lecia Sequist, Ryan J. Sullivan, Panagiotis M. Fidias, Alice Shaw, Rebecca S. Heist
Summary: This study aimed to find a new medical treatment for bone metastasis by testing the safety and efficacy of cabozantinib in patients with bone metastasis arising from non-breast, non-prostate malignant solid tumors. The results showed that cabozantinib demonstrated clinical activity and safety in heavily pretreated patients with bone metastasis and showed activity in patients with metastatic sarcoma.
Article
Oncology
Toni K. Choueiri, David F. McDermott, Jaime Merchan, Todd M. Bauer, Robert Figlin, Elisabeth Heath, M. Dror Michaelson, Edward Arrowsmith, Anishka D'Souza, Song Zhao, Ananya Roy, Rodolfo Perini, Donna Vickery, Scott S. Tykodi
Summary: In this study, the combination of belzutifan and cabozantinib showed promising antitumour activity in patients with pretreated clear cell renal cell carcinoma who had previously received immunotherapy. The findings provide rationale for further randomized trials with belzutifan in combination with a VEGFR tyrosine-kinase inhibitor.
Article
Oncology
Alexandre R. Zlotta, Leslie K. Ballas, Andrzej Niemierko, Katherine Lajkosz, Cynthia Kuk, Gus Miranda, Michael Drumm, Andrea Mari, Ethan Thio, Neil E. Fleshner, Girish S. Kulkarni, Michael A. SJewett, Robert G. Bristow, Charles Catton, Alejandro Berlin, Srikala S. Sridhar, Anne Schuckman, Adam S. Feldman, Matthew Wszolek, Douglas M. Dahl, Richard J. Lee, Philip J. Saylor, M. Dror Michaelson, David Miyamoto, Anthony Zietman, William Shipley, Peter Chung, Siamak Daneshmand, Jason A. Efstathiou
Summary: A retrospective analysis of 722 patients with muscle-invasive bladder cancer found no significant differences in survival outcomes between trimodality therapy and radical cystectomy, suggesting that trimodality therapy should be offered to all suitable candidates.
Article
Oncology
Bradley A. McGregor, Wanling Xie, Elio Adib, Walter M. Stadler, Yousef Zakharia, Aijai Alva, M. Dror Michaelson, Shilpa Gupta, Elaine T. Lam, Subrina Farah, Amin H. Nassar, Xiao X. Wei, Kerry L. Kilbridge, Lauren Harshman, Sabina Signoretti, Lynette Sholl, David J. Kwiatkowski, Rana R. McKay, Toni K. Choueiri
Summary: This study evaluated the efficacy of Sapanisertib in the treatment of refractory metastatic renal cell carcinoma (mRCC) and found that it had minimal activity independent of mTOR pathway alterations. Further therapeutic strategies are needed for patients with refractory mRCC.
JCO PRECISION ONCOLOGY
(2022)
